Blog

AstraZeneca raises sales and profit forecast as demand for therapies grows | Finance News


pharmaceutical sector, pharma sector, medicines, meds

The company previously expected revenue and profit to increase by a low double-digit to low-teens percentage. Photo: Bloomberg


Anglo-Swedish drugmaker AstraZeneca on Thursday raised its sales and profit forecast for 2024 and topped analyst expectations for second-quarter revenue, buoyed by demand for its therapies for cancer and rare diseases.

 


Sales in the company’s top business, oncology, grew 19% at constant currency rates to $5.33 billion and accounted for 41% of the total, while other divisions, such as rare diseases and respiratory and immunology, also raked in double-digit growth.

 


AstraZeneca’s drug pipeline has evolved significantly under CEO Pascal Soriot since he took over more than a decade ago, and new technologies such as antibody-drug conjugates are making up a rising proportion of its portfolio of future cancer therapies.


“In the year to date we have continued to make encouraging progress with several disruptive technologies … all of which have the potential to drive our growth beyond 2030,” CEO Soriot said.

 


AstraZeneca now expects both 2024 revenue and core earnings per share to increase by a mid-teens percentage at constant currency rates.

 


The company previously expected revenue and profit to increase by a low double-digit to low-teens percentage.

 


Analysts, on average, currently expect 2024 EPS of $8.11 and revenue of $51.62 billion – translating to growth of about 11.7% and 12.7%, respectively, according to LSEG IBES data.

 


Total revenue rose 17% on a constant-currency basis to $12.94 billion for the three months ended June, while core earnings came in at $1.98 per share for the largest London-listed company by market value.

 


Analysts, on average, were expecting profit of $1.98 per share on revenue of $12.6 billion for the quarter, according to a company-compiled consensus.




(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Jul 25 2024 | 12:39 PM IST



Source link

Shares:

Leave a Reply

Your email address will not be published. Required fields are marked *